---
title: "Galaxy Securities: The valuation of the pharmaceutical sector has recently shown a significant structural repair trend"
description: "Galaxy Securities research report points out that after the adjustment of the pharmaceutical sector's valuation, a structural repair trend has recently emerged. Although the holding level of public fu"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262743607.md"
published_at: "2025-10-26T04:21:32.000Z"
---

# Galaxy Securities: The valuation of the pharmaceutical sector has recently shown a significant structural repair trend

> Galaxy Securities research report points out that after the adjustment of the pharmaceutical sector's valuation, a structural repair trend has recently emerged. Although the holding level of public funds is below the historical average, it is expected that with policy support, the payment side will improve by 2025, benefiting innovative drugs and medical devices. Optimistic about pharmaceutical innovation, global central bank interest rate cuts will drive valuation increases; pharmaceutical investment and financing are expected to recover, and the secondary market's warming will drive the primary market; the medical device market is bottoming out and rebounding, with improved bidding data

Galaxy Securities research report believes that the pharmaceutical sector has undergone a long period of valuation adjustment and has recently shown a significant structural repair trend. However, the holding level of public funds remains below historical averages. In 2025, under the policy background supporting the development of commercial insurance, there is hope for marginal improvement on the payment side, and innovative drugs and medical devices are expected to benefit. 1) Continued optimism for pharmaceutical innovation: In the second half of the year, the business development of innovative drugs will continue, and the trend of interest rate cuts by major global central banks is expected to further boost valuations. 2) Pharmaceutical investment and financing are expected to recover: The warming of the secondary market will drive a rebound in investment and financing in the primary market, with continued improvement in CXO and upstream prosperity. 3) Medical devices are bottoming out and recovering: Tendering data has shown improvement, and the backlog of demand for trade-ins is gradually being released

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 百济神州 (6160.HK)：区间震荡拉锯，资金谨慎反复，医药板块新规前博弈趋于复杂 | 2 月 3 日收盘，百济神州全天波动显著，盘中高开回踩。资金虽然阶段性活跃，支撑了小幅反弹，但整体走势后继乏力。当前医药板块大势较为温和，大盘反弹引来部分长线资金试探入场，主力操作表现明显犹豫与反复，全日节奏以震荡偏强为主。 市场近期关注  | [Link](https://longbridge.com/en/news/274626559.md) |
| 百济神州 (6160.HK)：区间震荡拉锯，资金谨慎反复，医药板块新规前博弈趋于复杂 | 2 月 3 日收盘，百济神州全天波动显著，盘中高开回踩。资金虽然阶段性活跃，支撑了小幅反弹，但整体走势后继乏力。当前医药板块大势较为温和，大盘反弹引来部分长线资金试探入场，主力操作表现明显犹豫与反复，全日节奏以震荡偏强为主。 市场近期关注  | [Link](https://longbridge.com/en/news/274628892.md) |
| 百济神州 (6160.HK)：区间震荡拉锯，资金谨慎反复，医药板块新规前博弈趋于复杂 | 2 月 3 日收盘，百济神州全天波动显著，盘中高开回踩。资金虽然阶段性活跃，支撑了小幅反弹，但整体走势后继乏力。当前医药板块大势较为温和，大盘反弹引来部分长线资金试探入场，主力操作表现明显犹豫与反复，全日节奏以震荡偏强为主。 市场近期关注  | [Link](https://longbridge.com/en/news/274632359.md) |
| 百济神州 (6160.HK)：区间震荡拉锯，资金谨慎反复，医药板块新规前博弈趋于复杂 | 2 月 3 日收盘，百济神州全天波动显著，盘中高开回踩。资金虽然阶段性活跃，支撑了小幅反弹，但整体走势后继乏力。当前医药板块大势较为温和，大盘反弹引来部分长线资金试探入场，主力操作表现明显犹豫与反复，全日节奏以震荡偏强为主。 市场近期关注  | [Link](https://longbridge.com/en/news/274628090.md) |
| 百济神州 (6160.HK)：区间震荡拉锯，资金谨慎反复，医药板块新规前博弈趋于复杂 | 2 月 3 日收盘，百济神州全天波动显著，盘中高开回踩。资金虽然阶段性活跃，支撑了小幅反弹，但整体走势后继乏力。当前医药板块大势较为温和，大盘反弹引来部分长线资金试探入场，主力操作表现明显犹豫与反复，全日节奏以震荡偏强为主。 市场近期关注  | [Link](https://longbridge.com/en/news/274626001.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.